Feb 14, 2017 at 15:25 | Source: Moneycontrol.com
US generics business that accounts for nearly half of Sun Pharma sales grew at a moderate pace of 4 percent USD 507 million in the third quarter.
Jan 11, 2017 at 14:12 | Source: Moneycontrol.com
Lupin has received final approval for its Desoximetasone cream USP, 0.05 percent and Desoximetasone cream USP, 0.25 percent from the USFDA to market a generic equivalent of Taro Pharmaceuticals North America, Incs Topicort LP Emollient Cream, 0.05 percent and Taro Pharmaceuticals, Incs Topicort Cream, 0.25 percent.
Dec 15, 2016 at 07:44 | Source: Reuters
The two men are in talks with the government about a plea agreement, according to a source close to the negotiations who was not authorized to discuss the matter.
Dec 14, 2016 at 14:06 | Source: Moneycontrol.com
Lupin has received final approval for its Desoximetasone Ointment USP, 0.05 percent from the USFDA to market a generic version of Taro Pharms North's Topicort Ointment 0.05 percent.
Nov 22, 2016 at 21:14 | Source: PTI
Baldota, who has also been nominated to Taro's board of directors, is expected to begin his role as CEO on or about April 1, 2017, and will focus solely on the Taro business.
Nov 21, 2016 at 08:55 | Source: CNBC-TV18
Wockhardt, Sun Pharma, Tara, Novartis and other pharma company Perrigo are also in focus on account of reports from the US that there are lawsuits filed by Unions representing the New York Police Department on price collusion of two dermatology products.
Nov 17, 2016 at 09:12 | Source: PTI
"Taro Pharmaceuticals USA Inc is recalling the drug because of it being subpotent drug: out of specification assay values on stability for the active ingredient, zinc pyrithione," the latest Enforcement Report of health regulator USFDA has said.
Nov 09, 2016 at 17:48 | Source: CNBC-TV18
Healthcare major Sun Pharmaceutical Industries' second quarter profit is seen rising 52.3 percent year-on-year to Rs 1,685 crore on strong operational performance.
Nov 09, 2016 at 09:28 | Source: Moneycontrol.com
Taro Pharmaceutical Industries, the subsidiary of Sun Pharma, has reported a 7.2 percent degrowth in second quarter profit at USD 123.7 million despite higher operating income.
Nov 04, 2016 at 11:39 | Source: Moneycontrol.com
Pharma stocks, especially which have large exposure to United States, saw knee-jerk reaction on Friday after a media report indicated that US prosecutors are undertaking an investigation into the suspected price collusion.